Notice of Results

RNS Number : 2435X

Diaceutics PLC

27 August 2020

 

Diaceutics PLC

("Diaceutics" or the "Company")

Notice of results

Analyst & investor briefing

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces it will release its interim results for the six months ended 30 June 2020 on Monday, 7 September 2020.

Analyst briefing

The Company will host a ZOOM briefing for analysts which will take place at 9.30am on Monday 7 September 2020. If you would like to register to dial in, please contact Walbrook PR on 020 7933 8780 or email [e-mail].  

Investor briefing

The Company will also host a private investor call via ZOOM at 4.45pm on Monday, 7 September 2020. If you would like to register to dial in, please contact Walbrook PR on 020 7933 8780 or email   [e-mail] .

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Paul McManus		Mob: [phone]

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Group, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.  www.diaceutics.com

 

END

 

 

NORUNRVRRUUWUAR